Study record · Levocarnitine / L-carnitine
Levocarnitine improves cardiac function in hemodialysis patients with left ventricular hypertrophy
Ejection fraction improved in the levocarnitine group versus control in the analyzed cohort.
Key result
Ejection fraction improved in the levocarnitine group versus control in the analyzed cohort.
Study details
Study designMulticenter prospective randomized controlled trial (open-label)
PopulationMaintenance-hemodialysis patients with carnitine deficiency
Sample size222 randomized; 148 analyzed
RouteOral
Regimen / exposure20 mg/kg/day levocarnitine
Duration12 months
ComparatorNo levocarnitine
Primary endpoint / questionChange in left-ventricular ejection fraction
Safety resultDisease-specific clinical population; safety interpretation is tied to monitored dialysis care.
Key limitationsOpen-label design and attrition; not evidence for performance enhancement or fat loss in healthy users.
Registry / identifierPMID 26508680